|
1
|
Ayotte JD, Belaval M, Olson SA, Burow KR,
Flanagan SM, Hinkle SR and Lindsey BD: Factors affecting temporal
variability of arsenic in groundwater used for drinking water
supply in the United States. Sci Total Environ. 505:1370–1379.
2015. View Article : Google Scholar
|
|
2
|
Sorg TJ, Chen AS and Wang L: Arsenic
species in drinking water wells in the USA with high arsenic
concentrations. Water Res. 48:156–169. 2014. View Article : Google Scholar
|
|
3
|
Agusa T, Trang PT, Lan VM, Anh DH, Tanabe
S, Viet PH and Berg M: Human exposure to arsenic from drinking
water in Vietnam. Sci Total Environ. 488–489:562–569. 2014.
View Article : Google Scholar
|
|
4
|
Dummer TJ, Yu ZM, Nauta L, Murimboh JD and
Parker L: Geostatistical modelling of arsenic in drinking water
wells and related toenail arsenic concentrations across Nova
Scotia, Canada. Sci Total Environ. 505:1248–1258. 2015. View Article : Google Scholar
|
|
5
|
George CM, Sima L, Arias MH, Mihalic J,
Cabrera LZ, Danz D, Checkley W and Gilman RH: Arsenic exposure in
drinking water: An unrecognized health threat in Peru. Bull World
Health Organ. 92:565–572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
García-Esquinas E, Pollán M, Umans JG,
Francesconi KA, Goessler W, Guallar E, Howard B, Farley J, Best LG
and Navas-Acien A: Arsenic exposure and cancer mortality in a
US-based prospective cohort: The strong heart study. Cancer
Epidemiol Biomarkers Prev. 22:1944–1953. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saint-Jacques N, Parker L, Brown P and
Dummer TJ: Arsenic in drinking water and urinary tract cancers: a
systematic review of 30 years of epidemiological evidence. Environ
Health. 13:442014. View Article : Google Scholar
|
|
8
|
Gentry PR, Clewell HJ III, Greene TB,
Franzen AC and Yager JW: The impact of recent advances in research
on arsenic cancer risk assessment. Regul Toxicol Pharmacol.
69:91–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stoica A, Pentecost E and Martin MB:
Effects of arsenite on estrogen receptor-alpha expression and
activity in MCF-7 breast cancer cells. Endocrinology.
141:3595–3602. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren X, McHale CM, Skibola CF, Smith AH,
Smith MT and Zhang L: An emerging role for epigenetic dysregulation
in arsenic toxicity and carcinogenesis. Environ Health Perspect.
119:11–19. 2011. View Article : Google Scholar :
|
|
11
|
Gentry PR, McDonald TB, Sullivan DE, Shipp
AM, Yager JW and Clewell HJ III: Analysis of genomic dose-response
information on arsenic to inform key events in a mode of action for
carcinogenicity. Environ Mol Mutagen. 51:1–14. 2010.
|
|
12
|
Kijima I, Itoh T and Chen S: Growth
inhibition of estrogen receptor-positive and aromatase-positive
human breast cancer cells in monolayer and spheroid cultures by
letrozole, anastrozole, and tamoxifen. J Steroid Biochem Mol Biol.
97:360–368. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khanjani N, Jafarnejad AB and Tavakkoli L:
Arsenic and breast cancer: A systematic review of epidemiologic
studies. Rev Environ Health. 32:267–277. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schiff R, Massarweh S, Shou J and Osborne
CK: Breast cancer endocrine resistance: how growth factor signaling
and estrogen receptor coregulators modulate response. Clin Cancer
Res. 9(1 Pt 2): 447S–454S. 2003.PubMed/NCBI
|
|
16
|
Johnston SR, Saccani-Jotti G, Smith IE,
Salter J, Newby J, Coppen M, Ebbs SR and Dowsett M: Changes in
estrogen receptor, progesterone receptor, and pS2 expression in
tamoxifen-resistant human breast cancer. Cancer Res. 55:3331–3338.
1995.PubMed/NCBI
|
|
17
|
Kuukasjärvi T, Kononen J, Helin H, Holli K
and Isola J: Loss of estrogen receptor in recurrent breast cancer
is associated with poor response to endocrine therapy. J Clin
Oncol. 14:2584–2589. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Osborne CK and Schiff R: Mechanisms of
endocrine resistance in breast cancer. Annu Rev Med. 62:233–247.
2011. View Article : Google Scholar
|
|
19
|
Muñoz A, Chervona Y, Hall M, Kluz T,
Gamble MV and Costa M: Sex-specific patterns and deregulation of
endocrine pathways in the gene expression profiles of Bangladeshi
adults exposed to arsenic contaminated drinking water. Toxicol Appl
Pharmacol. 284:330–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peremartí J, Ramos F, Marcos R and
Hernández A: Arsenic exposure disrupts the normal function of the
FA/BRCA repair pathway. Toxicol Sci. 142:93–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Parodi DA, Greenfield M, Evans C, Chichura
A, Alpaugh A, Williams J and Martin MB: Alteration of mammary gland
development and gene expression by in utero exposure to arsenic.
Reprod Toxicol. 54:66–75. 2015. View Article : Google Scholar :
|
|
22
|
Tokar EJ, Diwan BA, Ward JM, Delker DA and
Waalkes MP: Carcinogenic effects of 'whole-life' exposure to
inorganic arsenic in CD1 mice. Toxicol Sci. 119:73–83. 2011.
View Article : Google Scholar
|
|
23
|
Waalkes MP, Liu J, Ward JM and Diwan BA:
Animal models for arsenic carcinogenesis: Inorganic arsenic is a
transplacental carcinogen in mice. Toxicol Appl Pharmacol.
198:377–384. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schrauzer GN, White DA, McGinness JE,
Schneider CJ and Bell LJ: Arsenic and cancer: Effects of joint
administration of arsenite and selenite on the genesis of mammary
adenocarcinoma in inbred female C3H/St mice. Bioinorg Chem.
9:245–253. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Hock JM, Sullivan C, Fang G, Cox
AJ, Davis KT, Davis BH and Li X: Activation of the p38
MAPK/Akt/ERK1/2 signal pathways is required for the protein
stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced
cell proliferation. J Cell Biochem. 111:1546–1555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu Y, Tokar EJ and Waalkes MP:
Arsenic-induced cancer cell phenotype in human breast epithelia is
estrogen receptor-independent but involves aromatase activation.
Arch Toxicol. 88:263–274. 2014. View Article : Google Scholar :
|
|
27
|
Tong D, Ortega J, Kim C, Huang J, Gu L and
Li GM: Arsenic Inhibits DNA Mismatch Repair by Promoting EGFR
Expression and PCNA Phosphorylation. J Biol Chem. 290:14536–14541.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bhattacharjee P, Banerjee M and Giri AK:
Role of genomic instability in arsenic-induced carcinogenicity. A
review. Environ Int. 53:29–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Benbrahim-Tallaa L, Webber MM and Waalkes
MP: Acquisition of androgen independence by human prostate
epithelial cells during arsenic-induced malignant transformation.
Environ Health Perspect. 113:1134–1139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome - biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cardenas A, Houseman EA, Baccarelli AA,
Quamruzzaman Q, Rahman M, Mostofa G, Wright RO, Christiani DC and
Kile ML: In utero arsenic exposure and epigenome-wide associations
in placenta, umbilical artery, and human umbilical vein endothelial
cells. Epigenetics. 10:1054–1063. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chou WC, Chung YT, Chen HY, Wang CJ, Ying
TH, Chuang CY, Tseng YC and Wang SL: Maternal arsenic exposure and
DNA damage biomarkers, and the associations with birth outcomes in
a general population from Taiwan. PLoS One. 9:e863982014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cui X, Wakai T, Shirai Y, Hatakeyama K and
Hirano S: Chronic oral exposure to inorganic arsenate interferes
with methylation status of p16INK4a and RASSF1A and induces lung
cancer in A/J mice. Toxicol Sci. 91:372–381. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ramirez T, Brocher J, Stopper H and Hock
R: Sodium arsenite modulates histone acetylation, histone
deacetylase activity and HMGN protein dynamics in human cells.
Chromosoma. 117:147–157. 2008. View Article : Google Scholar
|
|
35
|
Lu G, Xu H, Chang D, Wu Z, Yao X, Zhang S,
Li Z, Bai J, Cai Q and Zhang W: Arsenic exposure is associated with
DNA hyper-methylation of the tumor suppressor gene p16. J Occup Med
Toxicol. 9:422014. View Article : Google Scholar
|
|
36
|
Zhang TC, Schmitt MT and Mumford JL:
Effects of arsenic on telomerase and telomeres in relation to cell
proliferation and apoptosis in human keratinocytes and leukemia
cells in vitro. Carcinogenesis. 24:1811–1817. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang R, Li Y, Zhang A, Wang B, Xu Y, Xu
W, Zhao Y, Luo F and Liu Q: The acquisition of cancer stem
cell-like properties and neoplastic transformation of human
keratinocytes induced by arsenite involves epigenetic silencing of
let-7c via Ras/NF-κB. Toxicol Lett. 227:91–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Romagnolo DF, Donovan MG, Papoutsis AJ,
Doetschman TC and Selmin OI: Genistein prevents BRCA1 CpG
methylation and proliferation in human breast cancer cells with
activated aromatic hydrocarbon receptor. Curr Dev Nutr.
1:e0005622017. View Article : Google Scholar
|
|
39
|
Papoutsis AJ, Borg JL, Selmin OI and
Romagnolo DF: BRCA-1 promoter hypermethylation and silencing
induced by the aromatic hydrocarbon receptor-ligand TCDD are
prevented by resveratrol in MCF-7 cells. J Nutr Biochem.
23:1324–1332. 2012. View Article : Google Scholar
|
|
40
|
Jeffy BD, Hockings JK, Kemp MQ, Morgan SS,
Hager JA, Beliakoff J, Whitesell LJ, Bowden GT and Romagnolo DF: An
estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter
at an AP-1 site that binds Jun/Fos transcription factors:
Repressive effects of p53 on BRCA-1 transcription. Neoplasia.
7:873–882. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lothrop N, Wilkinson ST, Verhougstraete M,
Sugeng A, Loh MM, Klimecki W and Beamer PI: Home Water Treatment
Habits and Effectiveness in a Rural Arizona Community. Water.
7:1217–1231. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hough RL, Fletcher T, Leonardi GS,
Goessler W, Gnagnarella P, Clemens F, Gurzau E, Koppova K, Rudnai
P, Kumar R, et al: Lifetime exposure to arsenic in residential
drinking water in Central Europe. Int Arch Occup Environ Health.
83:471–481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kumar A, Adak P, Gurian PL and Lockwood
JR: Arsenic exposure in US public and domestic drinking water
supplies: A comparative risk assessment. J Expo Sci Environ
Epidemiol. 20:245–254. 2010. View Article : Google Scholar
|
|
44
|
Raessler M: The Arsenic Contamination of
Drinking and Groundwaters in Bangladesh: Featuring Biogeochemical
Aspects and Implications on Public Health. Arch Environ Contam
Toxicol. 75:1–7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ruiz-Ramos R, López- Carrillo L, Albores
A, Hernández-Ramírez RU and Cebrian ME: Sodium arsenite alters cell
cycle and MTHFR, MT1/2, and c-Myc protein levels in MCF-7 cells.
Toxicol Appl Pharmacol. 241:269–274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Necela BM, Crozier JA, Andorfer CA,
Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun
Z, Moreno-Aspitia A, et al: Correction: Folate receptor-α (FOLR1)
expression and function in triple negative tumors. PLoS One.
10:e01271332015. View Article : Google Scholar
|
|
47
|
Hosey AM, Gorski JJ, Murray MM, Quinn JE,
Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott
AN, et al: Molecular basis for estrogen receptor alpha deficiency
in BRCA1-linked breast cancer. J Natl Cancer Inst. 99:1683–1694.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lips EH, Mulder L, Oonk A, van der Kolk
LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S and Nederlof
PM: Triple-negative breast cancer: BRCAness and concordance of
clinical features with BRCA1-mutation carriers. Br J Cancer.
108:2172–2177. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nakareangrit W, Thiantanawat A,
Visitnonthachai D, Watcharasit P and Satayavivad J: Sodium arsenite
inhibited genomic estrogen signaling but induced pERα (Ser118) via
MAPK pathway in breast cancer cells. Environ Toxicol. 31:1133–1146.
2016. View Article : Google Scholar
|
|
50
|
Birgisdottir V, Stefansson OA,
Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG and Eyfjord JE:
Epigenetic silencing and deletion of the BRCA1 gene in sporadic
breast cancer. Breast Cancer Res. 8:R382006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bhattacharjee P, Sanyal T, Bhattacharjee S
and Bhattacharjee P: Epigenetic alteration of mismatch repair genes
in the population chronically exposed to arsenic in West Bengal,
India. Environ Res. 163:289–296. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Riedmann C, Ma Y, Melikishvili M, Godfrey
SG, Zhang Z, Chen KC, Rouchka EC and Fondufe-Mittendorf YN:
Inorganic Arsenic-induced cellular transformation is coupled with
genome wide changes in chromatin structure, transcriptome and
splicing patterns. BMC Genomics. 16:2122015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zara-Lopes T, Gimenez-Martins AP,
Nascimento-Filho CH, Castanhole-Nunes MM, Galbiatti-Dias AL,
Padovani-Júnior JA, Maniglia JV, Francisco JL, Pavarino EC and
Goloni-Bertollo EM: Role of MTHFR C677T and MTR A2756G
polymorphisms in thyroid and breast cancer development. Genet Mol
Res. 15:gmr82222016. View Article : Google Scholar
|
|
54
|
Ginter PS, McIntire PJ, Cui X, Irshaid L,
Liu Y, Chen Z and Shin SJ: Folate receptor alpha expression is
associated with increased risk of recurrence in triple-negative
breast cancer. Clin Breast Cancer. 17:544–549. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mauro M, Caradonna F and Klein CB:
Dysregulation of DNA methylation induced by past arsenic treatment
causes persistent genomic instability in mammalian cells. Environ
Mol Mutagen. 57:137–150. 2016. View Article : Google Scholar :
|
